Profound Medical Stock (NASDAQ:PROF)
Previous Close
$7.28
52W Range
$6.88 - $11.42
50D Avg
$7.73
200D Avg
$8.30
Market Cap
$178.80M
Avg Vol (3M)
$65.93K
Beta
0.83
Div Yield
-
PROF Company Profile
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.
PROF Performance
Peer Comparison
| Ticker | Company |
|---|---|
| FNA | Paragon 28, Inc. |
| OFIX | Orthofix Medical Inc. |
| ITGR | Integer Holdings Corporation |
| LUNG | Pulmonx Corporation |
| NPCE | NeuroPace, Inc. |
| SRDX | Surmodics, Inc. |
| LIVN | LivaNova PLC |
| NVRO | Nevro Corp. |
| KIDS | OrthoPediatrics Corp. |
| IRMD | IRadimed Corporation |
| SGHT | Sight Sciences, Inc. |
| SIBN | SI-BONE, Inc. |
| AORT | Artivion, Inc. |
| CVRX | CVRx, Inc. |